Agitation Clinical Trial
Official title:
Re-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient
PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST)
- The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the
sedation of agitated patients in the prehospital environment
- The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1
o The RASS is a well validated standardized score to measure a patient's agitation
- The secondary outcomes are
- Time until RASS returns to 0 or 1 if RASS <0
- Need for additional sedation
- Adverse effects (need for intubation, arrhythmia)
- Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying
haloperidol
- Identification of potential study patients will be per state protocols
- Exclusion Criteria for the study
- Age <18
- Pregnant
- Allergic to study medication
- Transport to hospital other than Mercy Fitzgerald Hospital
- Unable to reach medical command prior to giving medication
- When a paramedic identifies a possible study candidate, the paramedic will consult
medical command to see if the patient is appropriate for the study
- If the medical command agrees the patient is appropriate for the study, patients will be
randomized to
- Odd days: Haloperidol 5mg IM (age <65) or haloperidol 2.5 mg IM (age ≥65)
- Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age <65) or maximum of 2.5mg (age
≥65)
- The RASS will be documented by the prehospital providers every 5 minutes until arrival
at the hospital
- Once the patient arrives at the ED, the RASS will be documented in PICIS® by the
emergency department nurse at the time of triage and at a minimum of hourly until the
RASS =0 or 1 for 2 consecutive hours
- Questions may be directed to Dr. Isenberg at disenberg@mercyhealth.org or at (267)
205-6453
Richmond Agitation Sedation Scale
RASS RASS Description
- 4 Combative, violent, danger to staff
- 3 Pulls or removes tube(s) or catheters; aggressive
- 2 Frequent non-purposeful movement
- 1 Anxious, apprehensive, but not aggressive 0 Alert and calm
- 1 Awakens to voice (eye opening/contact) >10 sec
- 2 Light sedation, briefly awakens to voice (eye opening/contact) <10 sec
- 3 Moderate sedation, movement or eye opening. No eye contact
- 4 Deep sedation, no response to voice, but movement or eye opening to physical
stimulation
- 5 Unarousable, no response to voice or physical stimulation
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02525991 -
Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT01976754 -
Safety Study of Dexmedetomidine in Septic Patients
|
N/A | |
Completed |
NCT01217541 -
Collaboration Between Department of Old Age Psychiatry and Nursing Homes
|
N/A | |
Withdrawn |
NCT00786318 -
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
|
Phase 4 | |
Not yet recruiting |
NCT05974527 -
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
|
Phase 4 | |
Not yet recruiting |
NCT05522647 -
Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients.
|
||
Recruiting |
NCT02590744 -
Effects of Preoperative Using of Eye Patches on Prevention of Emergence Agitation After Cataract Surgery
|
N/A | |
Recruiting |
NCT02164773 -
Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation.
|
Phase 4 | |
Completed |
NCT01524367 -
Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery
|
Phase 4 | |
Completed |
NCT01021696 -
Pain in Patients With Dementia and Behavioural Disturbances
|
Phase 2/Phase 3 | |
Recruiting |
NCT05397639 -
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
|
Phase 3 | |
Terminated |
NCT03044249 -
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
|
Phase 2 | |
Completed |
NCT05165914 -
Midazolam Effect on Agitation Postnasal Surgery
|
N/A | |
Completed |
NCT04010305 -
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
|
Phase 1 | |
Completed |
NCT02720705 -
Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children
|
Phase 2/Phase 3 | |
Completed |
NCT02428283 -
Scalp Nerve Block on Emergence Agitation
|
Phase 4 | |
Completed |
NCT00457366 -
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
|
Phase 4 | |
Terminated |
NCT00315900 -
Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia
|
Phase 3 | |
Completed |
NCT01848158 -
Acupuncture to Improve Comfort of Children on a Ventilator in the Intensive Care Unit
|
N/A |